Laurenza A, Robbins J D, Seamon K B
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892.
Mol Pharmacol. 1992 Feb;41(2):360-8.
7-(2-Aminoethyl)aminocarbonyl-7-desacetylforskolin (7-AEC-Fsk) and 6-(2-aminoethyl)aminocarbonylforskolin (6-AEC-Fsk) were synthesized and tested for their ability to activate adenylyl cyclase and inhibit the high affinity binding of [3H]forskolin to bovine brain membranes. Forskolin and 7-AEC-Fsk were equipotent in activating adenylyl cyclase, with EC50 values of about 4 microM, whereas 6-AEC-Fsk had an EC50 of about 2 microM. 6-AEC-Fsk and 7-AEC-Fsk stimulated adenylyl cyclase about 7-fold over basal levels at 100 microM, whereas forskolin produced a 5-fold stimulation. Forskolin and 6-AEC-Fsk inhibited the binding of [3H]forskolin to bovine brain membranes with Kd values of 41 nM and 28 nM, respectively, whereas 7-AEC-Fsk had a Kd of 83 nM. The 3-(3-iodo-4-hydroxyphenyl)propionamide derivative of 6-AEC-Fsk (6-I-HPP-Fsk) was more potent than forskolin in inhibiting [3H]forskolin binding to bovine brain membranes, with a Kd of 14 nM. 6-AEC-Fsk was reacted with 125I-labeled Bolton-Hunter reagent to produce 6-125I-HPP-Fsk with a specific activity of 2175 Ci/mmol. 6-125I-HPP-Fsk bound to bovine brain membranes with a Kd of 13 nM and a Bmax of 3.8 pmol/mg of protein. Forskolin inhibited the binding of 6-125I-HPP-Fsk to bovine brain membranes with a Kd of 31 nM, whereas 1,9-dideoxyforskolin only slightly inhibited the binding at 10 microM. The binding of 6-125I-HPP-Fsk was not inhibited by agents that inhibit forskolin binding to the glucose transporter, such as D-glucose or cytochalasin B. There was no displaceable binding of 6-125I-HPP-Fsk to red blood cell membranes, which contain a large concentration of the glucose transporter. Pretreatment of bovine brain membranes with an alkylating derivative of forskolin, 7-bromoacetyl-7-desacetylforskolin (BrAcFsk), led to an irreversible decrease in the binding of [3H]forskolin and 6-125I-HPP-Fsk. The time dependence and concentration dependence for the BrAcFsk-induced decrease in [3H]forskolin binding sites were identical to those observed for the decrease in 6-125I-HPP-Fsk binding sites. 6-125I-HPP-Fsk binding was determined in human platelet membranes in the presence of Mg2+ alone and in combination with guanosine 5'-O-(3-thio)triphosphate (GTP gamma S) or AIF4-. The presence of GTP gamma S or AIF4- increased the binding of 6-125I-HPP-Fsk by 4.5-fold and 4-fold, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
合成了7-(2-氨基乙基)氨基甲酰基-7-去乙酰基福斯高林(7-AEC-Fsk)和6-(2-氨基乙基)氨基甲酰基福斯高林(6-AEC-Fsk),并测试了它们激活腺苷酸环化酶以及抑制[3H]福斯高林与牛脑膜高亲和力结合的能力。福斯高林和7-AEC-Fsk在激活腺苷酸环化酶方面效力相当,半数有效浓度(EC50)值约为4微摩尔,而6-AEC-Fsk的EC50约为2微摩尔。在100微摩尔时,6-AEC-Fsk和7-AEC-Fsk刺激腺苷酸环化酶的程度比基础水平高约7倍,而福斯高林产生5倍的刺激作用。福斯高林和6-AEC-Fsk抑制[3H]福斯高林与牛脑膜结合的解离常数(Kd)值分别为41纳摩尔和28纳摩尔,而7-AEC-Fsk的Kd为83纳摩尔。6-AEC-Fsk的3-(3-碘-4-羟基苯基)丙酰胺衍生物(6-I-HPP-Fsk)在抑制[3H]福斯高林与牛脑膜结合方面比福斯高林更有效,Kd为14纳摩尔。6-AEC-Fsk与125I标记的博尔顿-亨特试剂反应生成比活为2175居里/毫摩尔的6-125I-HPP-Fsk。6-125I-HPP-Fsk与牛脑膜结合的Kd为13纳摩尔,最大结合量(Bmax)为3.8皮摩尔/毫克蛋白质。福斯高林抑制6-125I-HPP-Fsk与牛脑膜结合的Kd为31纳摩尔,而1,9-二脱氧福斯高林在10微摩尔时仅轻微抑制结合。6-125I-HPP-Fsk的结合不受抑制福斯高林与葡萄糖转运蛋白结合的试剂如D-葡萄糖或细胞松弛素B的抑制。6-125I-HPP-Fsk与含有高浓度葡萄糖转运蛋白的红细胞膜没有可置换结合。用福斯高林的烷基化衍生物7-溴乙酰基-7-去乙酰基福斯高林(BrAcFsk)预处理牛脑膜,导致[3H]福斯高林和6-125I-HPP-Fsk的结合不可逆减少。BrAcFsk诱导的[3H]福斯高林结合位点减少的时间依赖性和浓度依赖性与6-125I-HPP-Fsk结合位点减少所观察到的相同。在仅存在Mg2+以及与鸟苷5'-O-(3-硫代)三磷酸(GTPγS)或AlF4-联合存在的情况下,在人血小板膜中测定6-125I-HPP-Fsk的结合。GTPγS或AlF4-的存在分别使6-125I-HPP-Fsk的结合增加4.5倍和4倍。(摘要截短于400字)